**Market conditions in late 2026 show a selective IPO window favoring smaller biotech offerings amid broader caution toward larger growth names.** Multiple high-profile candidates, including OpenAI and Oura, have delayed or shelved plans citing volatile equity markets, valuation gaps, and internal readiness factors, contributing to lower implied probabilities for several big-tech or AI-related listings by year-end. Year-to-date U.S. IPO volume stands at 254 deals, down modestly from 2025, with Q3 filings robust but conversion to priced offerings at only 62%—the lowest rate since late 2025. Recent activity includes Iambic Therapeutics and City Therapeutics pricing modest biotech IPOs in mid-October, while withdrawals such as Firmus underscore sensitivity to macro chop. Traders are pricing near-term catalysts around earnings visibility, Fed policy signals, and equity volatility measures, with resolution deadlines tightening as December 31, 2026 approaches.